Какие же прогностические факторы использовать при выборе тиреостатической терапии болезни Грейвса у детей?
https://doi.org/10.14341/ket20095223-29
Аннотация
Список литературы
1. Glaser N.S., Styne D.M. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study // Pediatrics. 2008. V. 121. N 3. P. 481–488.
2. Glaser N.S., Styne D.M. Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study // Pediatrics. 2008. V. 121. N 3. P. 481–488.
3. Kaguelidou F., Alberti C., Castanet M. et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment // J. Clin. Endocrin. Metab. 2008. V. 93. N10. P. 3817–3826.
4. Кияев А.В., Сумин М.Н., Савельев Л.И. Выбор метода лечения болезни Грейвса у детей // Пробл. эндокринол. 2008. № 1. С. 29–36.
5. Смирнова Г.Е., Прокофьев С.А., Зверева Я.С. и др. Клиническое значение и прогностическая роль антител к рецептору ТТГ у детей с болезнью Грейвса // Клин. и экспер. тиреоидол. 2006. № 3 С. 44–50.
6. Barrio R., Lopez)Capape M., Martinez)Badas I. et al. Graves’ disease in children and adolescents: response to long-term treatment // Acta. Paediatr. 2005. V. 94. N 11. P. 1583–1589.
7. Glaser N.S., Styne D.M. Predictors of early remission of hyperthyroidism in children // J. Clin. Endocrin. Metab. 1997. V. 82. N 6. P. 1719-1726.
8. Gruneiro)Papendieck L., Chiesa A., Finkielstain G., Heinrich J.J. Pediatric Graves’ disease: outcome and treatment // Pediatr. Endocrinol. Metab. 2003. V.16. N 9. P. 1249–1255.
9. Jaruratanasirikul S., Leethanaporn K., Sriplung H. Thyrotoxicosis in children: treatment and outcome // J. Med. Assoc. Thai. 2006. V. 89. N 7. P. 967–973.
10. Lasar L., Kalter)Leibovici O., Pertzelan A. et al. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients // J. Clin. Edocrinol. Metab. 2000. V. 10. P. 3878–3882.
11. Lippe B.M., Landau E.M., Kaplan S.A. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years // J. Clin. Endocrinol. Meteb. 1987. V. 64. P. 1241–1245.
12. Mussa G.C., Corrias A., Silvestro L. et al. Factors at onset predictive of lasting remission in pediatric patients with Graves’ disease followed for at least three years // J. Pediatr. Endocrinol. Metab. 1999. V. 12. N 4. P. 537–541.
13. Michelangeli V., Poon C., Taft J. et al. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs // Thyroid. 1998. V. 8. N 2. P. 119–124.
14. Takasu N., Yamashiro K., Komiya I. et al. Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment // Thyroid. 2000. V. 10. N 10. P. 891–896.
15. Cappelli C., Gandossi E., Castellano M. et al. Prognostic value of thyrotopin receptor antibodies (TRAb) in Grave’s disease: a 120 months prospective study // Endocr. J. 2007. V. 54. N 5. P. 713–720.
Рецензия
Для цитирования:
Kiyaev A.V., Sumin M.N. Какие же прогностические факторы использовать при выборе тиреостатической терапии болезни Грейвса у детей? Клиническая и экспериментальная тиреоидология. 2009;5(2):23-29. https://doi.org/10.14341/ket20095223-29
For citation:
, Kakie zhe prognosticheskie faktory ispol'zovat' pri vybore tireostaticheskoy terapii bolezni Greyvsa u detey? Clinical and experimental thyroidology. 2009;5(2):23-29. (In Russ.) https://doi.org/10.14341/ket20095223-29

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).